Cardiomyocytes RNA silencing guide

Cardiomyocytes present unique biological barriers that cause conventional transfection to fail or create irreversible electromechanical disruption:

Electroporation-induced calcium overload and hypercontractility

Cardiomyocyte function depends on precise calcium cycling: action potential opens voltage-gated L-type Ca²⁺ channels (LTCC), small calcium influx triggers ryanodine receptor 2 (RYR2) opening, massive calcium release from sarcoplasmic reticulum (SR) drives sarcomere contraction, SERCA2A pumps calcium back into SR for relaxation. Electroporation creates non-selective membrane pores that allow uncontrolled calcium influx, bypassing physiological regulation. This can cause: (1) intracellular calcium overload, far above normal systolic levels, (2) hypercontractility and contracture (sustained contraction, may not relax), (3) SR calcium depletion (SERCA2A cannot compensate for continuous leak), (4) mitochondrial calcium uptake leading to mitochondrial permeability transition pore opening and ATP depletion, (5) calcium-activated proteases (calpains) damage sarcomeric proteins. Result: can cause significant viability loss in primary adult cardiomyocytes and iPSC-CMs (outcomes vary with protocol, cell source, and culture conditions).

High impact

Extremely low transfection efficiency in primary adult cardiomyocytes

Primary adult cardiomyocytes are post-mitotic and terminally differentiated. Lipofection depends on the lipoplex being taken up and released from the endosome, so how much cargo reaches the cytosol depends on the reagent, and it is inefficient in this preparation. The cells it does not reach stay untreated, which leaves a mosaic population that confounds a functional readout.

High impact

Disruption of T-tubule organization and electrical coupling

Mature adult cardiomyocytes have transverse tubules (t-tubules): sarcolemmal invaginations that penetrate deep into the cell, placing L-type calcium channels in close proximity to RYR2 on the SR for efficient excitation-contraction coupling. Electroporation can disrupt t-tubule structure and organization within hours through membrane damage, protein mis-localization, and loss of t-tubule density. This can create dyssynchronous calcium release (calcium waves instead of uniform rise), reduced contractile force, and arrhythmogenic calcium sparks. iPSC-CMs have immature or absent t-tubules initially, but electroporation can still disrupt developing sarcolemmal structures.

High impact

Arrhythmogenic effects and spontaneous beating disruption

iPSC-CMs exhibit spontaneous automaticity: they beat rhythmically without external pacing due to pacemaker currents (If/HCN channels, spontaneous calcium release). Electroporation and lipofection disrupt this delicate balance through altered membrane potential, disrupted calcium handling, and ion channel damage. This causes: (1) arrhythmic beating (irregular, pausing, or fibrillation-like activity), (2) slowed beating rate or complete cessation of spontaneous activity, (3) early afterdepolarizations (EADs) and delayed afterdepolarizations (DADs) indicative of proarrhythmic state. For arrhythmia studies (hERG, SCN5A, RYR2), transfection-induced arrhythmias mask or confound genetic arrhythmia phenotypes.

High impact

iPSC-CM immaturity and heterogeneity

iPSC-derived cardiomyocytes recapitulate fetal/neonatal developmental stage, not adult physiology. Characteristics include: round/disorganized morphology (vs. rod-shaped adult), spontaneous automaticity (vs. quiescent adult), immature ion channel expression (different I_Kr, I_Na kinetics), glycolytic metabolism (vs. fatty acid oxidation in adult), and lack of t-tubules. Differentiation protocols yield mixed populations: ventricular-like (60-80%, MLC2v+), atrial-like (10-30%, MLC2a+), nodal-like (5-10%, HCN4+). This heterogeneity complicates transfection optimization and phenotype interpretation. Transfection efficiency varies by subtype, with atrial-like cells more sensitive to damage.

Medium impact

Post-mitotic nature and limited regeneration capacity

Adult cardiomyocytes are post-mitotic: they exit the cell cycle in early postnatal life. Damage from transfection is permanent (no regeneration from division to replace dead cells). Primary adult cardiomyocyte cultures lose 40-60% of cells within 48h of isolation due to anoikis (loss of extracellular matrix contacts) and re-oxygenation injury. Additional transfection stress pushes survival below viable experimental thresholds. For long-term studies (>5 days), cell loss becomes prohibitive. iPSC-CMs show minimal proliferation (<1% Ki67+), so similar concerns apply.

Medium impact

Method comparison

Gene silencing in cardiomyocytes with no transfection reagent

Electromechanical function during knockdown

Key benefits

• Enables patient-specific disease modeling. Knock down disease genes in patient iPSC-CMs: hERG in LQT2 patient cells, MYBPC3 in HCM patient cells, TTN in DCM patient cells. Test allele-specific knockdown (mutant vs. wild-type) to model haploinsufficiency or dominant-negative effects. Correlate genotype with phenotype (FPD prolongation, hypercontractility, reduced contractility).
• Arrhythmia modeling without transfection artifacts. Electroporation causes arrhythmias via calcium overload (confounds genetic arrhythmia studies). AUMsilence sdASO preserves baseline electrophysiology; observed arrhythmias (EADs, DADs, irregular beating) result from target gene knockdown, not transfection artifact. Critical for hERG, SCN5A, RYR2 studies.
• Cardiotoxicity screening with preserved stress response. Test cardioprotective gene knockdown strategies: TOP2B knockdown protects from doxorubicin cardiotoxicity. Cells remain viable and functional for subsequent drug challenge (doxorubicin, trastuzumab, tyrosine kinase inhibitors). Cells damaged by electroporation can fail to survive a second stress of this kind.
• Viability for multi-day functional assays. Viability is maintained through 96h treatment. Enables sequential assays on same cells: Day 0-4 (ASO treatment), Day 4 (MEA baseline), Day 5 (drug challenge), Day 6 (stress test). Primary adult CMs typically survive 48-72h (sufficient for critical experiments within narrow window).
• Compatible with high-throughput screening. Seed iPSC-CMs in 96-well MEA plates, add AUMsilence sdASO directly to medium (no transfection optimization per well). Screen gene knockdown panel (10-20 genes) in parallel. Reduces reagent costs vs. electroporation (no electroporation plates or buffers) and time (no optimization per target).

Cell types and applications

• iPSC-derived cardiomyocytes (commercial or in-house differentiated)
• Primary adult cardiomyocytes (mouse, rat, human isolated by Langendorff)
• Patient iPSC-CMs for genetic disease modeling (LQT, Brugada, CPVT, HCM, DCM)
• Arrhythmia studies (hERG, SCN5A, KCNQ1, RYR2, CACNA1C knockdown)
• Heart failure modeling (SERCA2A, phospholamban, calcineurin, NFAT signaling)
• Genetic cardiomyopathy (MYBPC3 HCM, TTN DCM, troponin mutations)
• Cardiotoxicity screening (TOP2B for doxorubicin, ERBB2 for trastuzumab)
• Calcium handling studies (RYR2, SERCA2A, calsequestrin, calmodulin)
• Electrical coupling and conduction (connexin-43, gap junctions)
• Multielectrode array (MEA) electrophysiology for proarrhythmia screening
• Patch-clamp studies (action potentials, ion current isolation)
• Drug discovery and safety pharmacology (hERG liability, QT screening)
• Teaching labs and core facilities (reproducible CM manipulation)

• Learn more about AUMsilence™ sdASO™

Alternative products

• AUMsilence™ toASO™ When to use: Not recommended for cardiomyocytes. Cardiomyocytes require highest stability ASO chemistry to avoid membrane disruption and preserve calcium handling. Use AUMsilence sdASO.
• Custom ASO design service When to use: For allele-specific knockdown in patient iPSC-CMs (LQT, HCM, DCM mutations), multi-gene arrhythmia panels, or species-specific ASOs (mouse, rat primary CMs). AUM scientists design and validate 3-5 candidates per target.

Optimized protocols for iPSC-derived cardiomyocytes and primary adult cardiomyocytes. Preserves beating, calcium handling, and contractile function. No transfection reagents required.

Quick start protocol (iPSC-cardiomyocytes)

1. 01Culture iPSC-CMs on basement membrane matrix or fibronectin in cardiomyocyte maintenance medium
2. 02Add AUMsilence™ sdASO™ directly to culture medium at 10 μM (no transfection reagent)
3. 03Incubate 72-96 hours at 37°C, 5% CO₂ (maintain spontaneous beating)
4. 04Validate knockdown by qRT-PCR (72h after treatment) and Western blot or flow cytometry (96h after treatment)
5. 05Verify beating maintained: optical tracking, fluorescent calcium imaging, video microscopy
6. 06Perform functional assays: multielectrode array (MEA), patch-clamp, contractility, calcium transients

Cell-type-specific protocols

iPSC-derived cardiomyocytes (iPSC-CMs)

Human cardiomyocytes from directed differentiation: renewable, patient-specific disease modeling

1. 01

   Step 1: iPSC-CM differentiation or commercial sourcing

   Option 1: Differentiate iPSCs using small molecule protocol with CHIR99021 (GSK3β inhibitor/WNT activator, Day 0-1), then IWP-2 or IWP-4 (WNT inhibitor, Day 3-5), followed by spontaneous beating on Day 8-12. Purify by metabolic selection (glucose-depleted, lactate-supplemented medium, Day 10-20 to eliminate non-cardiomyocytes). Option 2: Purchase commercial iPSC-derived cardiomyocytes from multiple vendors. Thaw and plate per manufacturer protocol on basement membrane matrix or fibronectin (10 μg/cm²). Culture in cardiomyocyte maintenance medium (RPMI 1640 + B27 supplement, or vendor-specific medium). Expect spontaneous synchronous beating within 24-48h post-plating.

   Materials: iPSC-CMs (commercial or in-house), basement membrane matrix or fibronectin, cardiomyocyte medium

   Note: Day 30-60 post-differentiation iPSC-CMs are optimal for ASO studies: stable phenotype, spontaneous beating. Verify beating and viability (>80% cTnT+ by flow, >80% viable by viability/cytotoxicity staining).

   Timing: Day -60 to Day 0 (if differentiating); or Day -3 to Day 0 (if using commercial)

2. 02

   Step 2: Seeding for ASO treatment

   Dissociate iPSC-CM clusters to single cells or small aggregates using recombinant cell dissociation enzyme (5-10 min, 37°C). Quench with cardiomyocyte medium + 10% FBS. Seed at 1-2 × 10⁵ cells/cm² in 24-well plates (500 μL medium/well) or 96-well plates for high-throughput (100 μL/well). Coat plates with basement membrane matrix (diluted 1:100) or fibronectin (10 μg/cm²). Include ROCK inhibitor (Y-27632, 10 μM) in medium for first 24h to enhance survival post-dissociation. Allow cells to attach and resume beating (24-48h).

   Materials: Recombinant cell dissociation enzyme, ROCK inhibitor, basement membrane matrix or fibronectin

   Note: iPSC-CMs may pause beating during dissociation stress (normal). Beating resumes within 24-48h. If no beating by 48h, cells are too damaged (poor quality starting population or excessive dissociation).

   Timing: Day -2

3. 03

   Step 3: AUMsilence sdASO treatment of iPSC-CMs

   At Day 0 (cells attached, beating), add AUMsilence sdASO directly to medium at 10 μM final concentration. For 500 μL in 24-well, add 5 μL of 1 mM AUMsilence sdASO stock. Do NOT change medium during incubation (medium change stresses cells and disrupts beating). AUMsilence sdASOs bind proteins on the cell surface and are taken up by endocytosis, followed by endosomal escape to reach the cytosol and nucleus for RNase H1-mediated target degradation. Maintain at 37°C, 5% CO₂.

   Materials: AUMsilence sdASO (1 mM stock in nuclease-free water)

   Note: The recommended working range is 5-20 μM, with a starting concentration of 10 μM. Beating should continue uninterrupted throughout treatment.

   Timing: Day 0

4. 04

   Step 4: Incubation and functional monitoring

   Incubate 72-96 hours. Monitor daily: (1) Spontaneous beating: observe under brightfield microscope. Beating should be maintained at a rate that is stable against each well's own baseline before treatment. Record video for offline analysis (beat rate, contraction amplitude). (2) Morphology: cells should maintain spread morphology, sarcomeric striations visible under phase contrast. (3) Viability: no widespread detachment or cell rounding. If targeting critical ion channels (hERG, SCN5A, RYR2), may observe beating rate or rhythm changes as expected phenotype, not toxicity.

   Materials: Inverted microscope with video recording capability

   Note: Critical: AUMsilence sdASO does NOT disrupt baseline beating or calcium handling. If arrhythmic beating develops, this indicates target gene knockdown phenotype (e.g., hERG knockdown causes EADs), not ASO toxicity. Include non-targeting control to verify.

   Timing: Days 0-4

5. 05

   Step 5: Validation of knockdown

   At 72h after treatment: qRT-PCR for mRNA, expect 70-95% knockdown. At 96h: protein validation by (1) Western blot for total protein (ion channels, sarcomeric proteins, signaling molecules), (2) Immunofluorescence: fix cells (4% PFA, 15 min), permeabilize (0.1% Triton X-100), stain for target protein and sarcomere markers (α-actinin, cTnT). (3) Flow cytometry: dissociate with recombinant cell dissociation enzyme, intracellular staining for target protein. Include a viability dye.

   Materials: RNA extraction, qPCR reagents, antibodies (Western, IF, flow), recombinant cell dissociation enzyme

   Note: For membrane proteins (ion channels, connexins): use immunofluorescence, which preserves localization. For sarcomeric proteins: IF or Western. For secreted proteins (ANP, BNP): ELISA on supernatants.

   Timing: Days 3-4

6. 06

   Step 6: Functional assays post-knockdown

   At 96h post-ASO, perform electrophysiological and contractility assays: (1) Calcium imaging: load with fluorescent calcium indicator (1-5 μM, 30 min), wash, image calcium transients during spontaneous beating or paced activity. Measure: peak [Ca²⁺]ᵢ amplitude, transient duration, diastolic [Ca²⁺]ᵢ, decay kinetics (tau, reflects SERCA2A function). (2) Multielectrode array (MEA): plate iPSC-CMs on MEA chips, measure extracellular field potentials. Analyze: beat rate, field potential duration (FPD, surrogate for QT interval), conduction velocity, arrhythmia incidence. (3) Contractility: video-based motion tracking (open-source motion analysis software for ImageJ) to quantify contraction amplitude, contraction/relaxation velocities. (4) Patch-clamp electrophysiology: action potential recording (current clamp) or ion current measurement (voltage clamp for I_Na, I_Kr, I_CaL).

   Materials: Calcium dyes (Fluo-4, Fura-2), MEA system, patch-clamp rig, ImageJ

   Note: Expected results depend on target: hERG knockdown leads to prolonged FPD (QT prolongation). SCN5A knockdown leads to reduced upstroke velocity. RYR2 knockdown leads to reduced calcium transient amplitude. SERCA2A knockdown leads to prolonged calcium decay and diastolic calcium elevation. MYBPC3 knockdown leads to hypercontractility (HCM phenotype).

   Timing: Days 4-7

Primary adult cardiomyocytes (isolated from hearts)

Mature rod-shaped CMs with organized sarcomeres: gold standard for adult cardiac physiology but fragile

1. 01

   Step 1: Cardiomyocyte isolation (Langendorff perfusion)

   Isolate from mouse, rat, or human hearts using Langendorff retrograde perfusion. Cannulate aorta, perfuse with oxygenated Tyrode solution, then collagenase II + protease blend (15-30 min at 37°C) to digest extracellular matrix. Dissociate tissue by gentle trituration. Filter through 100 μm mesh. Perform calcium reintroduction with stepwise increases: [Ca²⁺] from 0 to 50 μM to 100 μM to 200 μM to 1 mM over 30 min to prevent calcium overload. Purify by gravity settling (rod-shaped CMs settle, dead cells/debris remain suspended). Yield: 60-80% viable rod-shaped CMs (trypan blue exclusion).

   Materials: Langendorff apparatus, collagenase II, protease blend, Tyrode solution, laminin coating

   Note: Primary adult CMs are extremely fragile. Gentle handling essential. Cannot passage. Use within 24-48h of isolation (cells dedifferentiate and lose rod shape if cultured >3 days).

   Timing: Day 0 (isolation day)

2. 02

   Step 2: Plating and culture

   Plate immediately post-isolation on laminin-coated plates (20 μg/cm², coat 2h at 37°C). Seed at 1-2 × 10⁴ cells/cm² in Medium 199 + 5% FBS + ITS (insulin-transferrin-selenium) + BDM (2,3-butanedione monoxime, 10 mM, optional to prevent hypercontractility during plating). Allow attachment for 2-4h, then replace with serum-free medium (Medium 199 + ITS, no BDM). Cells attach and spread within 2-6h, adopt quiescent state (do not beat spontaneously unless paced).

   Materials: Laminin, Medium 199, ITS, BDM

   Note: Adult CMs are quiescent (non-beating) unless electrically paced or treated with β-agonists (isoproterenol). This is normal and contrasts with iPSC-CMs which beat spontaneously.

   Timing: Day 0 (post-isolation)

3. 03

   Step 3: AUMsilence sdASO treatment

   At 4-6h post-plating (cells attached), add AUMsilence sdASO at 10 μM. Incubate 48-72h. Do NOT change medium (stresses cells). Monitor morphology: rod-shaped morphology should be maintained. Can achieve 70-95% knockdown.

   Materials: AUMsilence sdASO

   Note: Primary CMs cannot be cultured >72-96h (dedifferentiation, loss of rod shape). Plan experiments for Day 2-3 post-isolation.

   Timing: Day 0-3

4. 04

   Step 4: Functional validation in primary CMs

   At 48-72h post-ASO: (1) Field stimulation and calcium imaging: pace cells at 1 Hz (platinum electrodes, 5 ms pulses), load with calcium dye (Fluo-4 AM), measure calcium transients. Analyze peak amplitude, decay (tau), diastolic Ca²⁺. (2) Contractility: video sarcomere shortening using edge-detection (sarcomere length measurement system) or video microscopy with sarcomere length tracking. Measure: fractional shortening (%), contraction/relaxation velocities. (3) Patch-clamp: action potential clamp or ion currents. Primary adult CMs have mature ion channel expression and are physiologically relevant for drug screening.

   Materials: Field stimulator, calcium imaging, sarcomere length detection system

   Note: Primary adult CMs gold standard for mature cardiac physiology but low throughput. Use for final validation after iPSC-CM studies.

   Timing: Days 2-3

Patient iPSC-CMs for disease modeling

Disease-specific iPSC lines (familial arrhythmias, cardiomyopathies) differentiated to cardiomyocytes

1. 01

   Step 1: Patient iPSC line selection and validation

   Use patient-derived iPSCs carrying disease mutation: long QT (KCNH2, KCNQ1, SCN5A mutations), CPVT (RYR2 mutations), HCM (MYBPC3, MYH7, TNNT2 mutations), DCM (TTN, LMNA mutations). Validate: pluripotency (OCT4, NANOG, TRA-1-60), normal karyotype, confirm mutation by Sanger sequencing or whole-genome sequencing. Isogenic control (gene-corrected using genome editing) controls for genetic background but is not required; can use healthy donor iPSC-CMs.

   Materials: Patient iPSC line, sequencing

   Note: Many disease iPSC-CM lines commercially available from multiple vendors or from repositories.

   Timing: Baseline characterization

2. 02

   Step 2: Differentiation to cardiomyocytes

   Differentiate patient iPSCs to cardiomyocytes using standard protocol (Day 30-60 post-differentiation optimal). Disease phenotypes typically emerge at maturation (Day 30-90): LQT shows prolonged FPD on MEA and EADs on patch-clamp; CPVT shows delayed afterdepolarizations (DADs) with β-agonist (isoproterenol); HCM shows hypercontractility and calcium transient prolongation; DCM shows reduced contractile force and calcium transient amplitude.

   Materials: Cardiac differentiation reagents, electrophysiology equipment

   Note: Some phenotypes require stress (β-agonist for CPVT, pacing for LQT). Baseline phenotype may be subtle; compare to control.

   Timing: Days 0-60 (differentiation)

3. 03

   Step 3: Allele-specific or gene-specific ASO treatment

   Treat mature patient iPSC-CMs (Day 30-60) with AUMsilence sdASO targeting: (1) Mutant allele specifically (if SNP or mutation-specific ASO designed), (2) Total gene knockdown (both alleles) to test if reducing gene expression rescues phenotype (e.g., 50% RYR2 reduction may prevent CPVT), (3) Modifier genes (e.g., knockdown calcineurin in HCM to prevent hypertrophy). Incubate 72-96h, measure rescue: normalized FPD (LQT), eliminated DADs (CPVT), reduced hypercontractility (HCM), improved contractility (DCM if targeting maladaptive genes).

   Materials: Allele-specific AUMsilence sdASO (custom design), functional assays

   Note: Allele-specific targeting requires custom ASO design (contact AUM). Test knockdown specificity: qPCR with allele-specific primers or allele-specific antibodies if available.

   Timing: Days 60-67

Essential controls for cardiomyocyte experiments

• Untreated cardiomyocytes: Baseline beating rate, calcium transients, contractility, action potential morphology
  Culture identically but without ASO. Critical for verifying no functional disruption from ASO treatment itself.
• Non-targeting control ASO: Control for non-specific ASO effects on cardiomyocyte function
  Use AUM non-targeting control at 10 μM. Measure beating, calcium handling, and viability; should match untreated exactly.
• Positive control for disease phenotype: Validate assays detect known arrhythmogenic or functional changes
  For LQT studies: E-4031 (hERG blocker, 1 μM) prolongs FPD. For calcium: thapsigargin (SERCA inhibitor) reduces calcium transient decay. For contractility: blebbistatin (myosin inhibitor) reduces contraction.
• Viability and beating assessment: Ensure ASO does not cause toxicity or calcium overload
  At 24h, 72h, 96h after treatment: (1) Beating rate and rhythm: video record, count beats/min. (2) Viability: viability/cytotoxicity staining or cTnT release in supernatant (cardiac troponin T release = cell death). (3) Morphology: maintain spread morphology (iPSC-CMs) or rod shape (primary adult).

Optimization strategies for cardiomyocyte applications

Validation covers the cell's electrical activity, its calcium handling, its contraction and its sarcomere organization.

Multielectrode array (MEA) electrophysiology

Fluorescent calcium imaging

Patch-clamp electrophysiology

Contractility assay (sarcomere shortening, video motion tracking)

Immunofluorescence and sarcomere organization

Critical controls for cardiomyocyte validation

• Untreated cardiomyocytes: Baseline electrophysiology, calcium handling, contractility
  Culture identically without ASO. Measure beat rate, FPD, calcium transients, and contraction; should match non-targeting control. If ASO-treated cells differ from both untreated and non-targeting control, this suggests target gene knockdown phenotype.
• Non-targeting control ASO: Control for non-specific ASO effects on cardiomyocyte electromechanical function
  Use AUM non-targeting control ASO at 10 μM. Verify no change in beat rate, FPD, calcium transients, contractility vs. untreated. If non-targeting ASO alters function, suggests off-target toxicity.
• Pharmacological mimicry of genetic phenotype: Validate that knockdown phenotype matches known drug effects on target
  For hERG knockdown: compare to E-4031 (hERG blocker); both should prolong FPD. For RYR2: compare to dantrolene (RYR inhibitor). For SERCA: compare to thapsigargin (SERCA inhibitor). Concordance validates on-target phenotype.
• Viability and beating maintenance: Ensure ASO does not cause calcium overload or electromechanical uncoupling
  Monitor throughout treatment (Day 1, 2, 3, 4): beating rate and rhythm (should be stable, unless targeting pacemaker genes), viability (by viability/cytotoxicity dual staining), morphology (spread shape for iPSC-CMs, rod shape for primary adult), cTnT release in supernatant (elevated cTnT = cell death).